Companies in Vidharbha have been ordered to test medications for cancer-causing contaminants.

Vidarbha has some of the around 40 drug manufacturers who have been urged to have their products tested for nitrosamine impurities . Several drugs being investigated include heartburn, acid reflux, stomach ulcers, tuberculosis, angiotensin II receptor blockers for lowering blood pressure, blood sugar, anti-smoking agents, and others .

NAGPUR: Drug manufacturers have been warned against using carcinogenic or cancer-causing nitrosamines in their products above the permissible threshold.According to the investigation, Vidarbha has some of the around 40 drug manufacturers who have been urged to have their products tested for nitrosamine impurities.Several drugs being investigated include heartburn, acid reflux, stomach ulcers, tuberculosis, angiotensin II receptor blockers for lowering blood pressure, blood sugar, anti-smoking agents, and others.Although many drugs have been banned from the market, their manufacturing is being monitored to reduce the impurities in them within the acceptable ranges.

Following the discovery of impurities in some of these drugs by the US Food and Drug Administration, the global pharmaceutical industry took over in 2018.At least seven species of nitrosamine impurities, such as NDMA, had been alerted by the US FDA.The United Drug Standard Control Organization (CDSCO) and the Indian Pharmacopoeia Commission (IPC) have taken the situation seriously.Last week, the Food and Drugs Administration (FDA) in Nagpur held an online webinar with about 40 Vidarbha pharmaceutical companies to inform them of their contamination and follow stringent manufacturing practices as laid out in the Drug and Cosmetics Act, 1940.

There are only a few laboratories that can test nitrosamine impurities.According to an official, the bulk of them carry high testing loads and queues, and that Vidarbha's manufacturers have already sent their samples, and the results are being anticipated.Officials also stated that scientists around the world are searching for the source of nitrosamine impurities and how they are formed.According to a source, the source of the impurities is still being investigated, whether those constituents are active pharmaceutical ingredients (API), reagents, solvents, excipients, or other raw materials, or the process of manufacturing and storage.